Testicular Function After Long-Term Methylphenidate Treatment in Boys with Attention-Deficit/Hyperactivity Disorder

被引:6
|
作者
Wang, Liang-Jen [1 ,2 ]
Lee, Sheng-Yu [3 ,4 ]
Chou, Wen-Jiun [1 ,2 ]
Lee, Min-Jing [1 ,2 ]
Tsai, Ching-Shu [1 ,2 ]
Lee, Tung-Liang [5 ]
Yang, Chun-Ju [6 ]
Yang, Kang-Chung [6 ]
Chen, Chih-Ken [6 ,7 ,8 ]
Shyu, Yu-Chiau [6 ,9 ,10 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Dept Child & Adolescent Psychiat, Kaohsiung, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan
[3] Kaohsiung Vet Gen Hosp, Dept Psychiat, Kaohsiung, Taiwan
[4] Kaohsiung Med Univ, Sch Med, Grad Inst Med, Dept Psychiat,Coll Med, Kaohsiung, Taiwan
[5] Soochow Univ, Dept Microbiol, Taipei, Taiwan
[6] Keelung Chang Gung Mem Hosp, Community Med Res Ctr, Keelung 204, Taiwan
[7] Chang Gung Mem Hosp, Dept Psychiat, Keelung, Taiwan
[8] Chang Gung Univ, Coll Med, Keelung, Taiwan
[9] Acad Sinica, Inst Mol Biol, Taipei, Taiwan
[10] Chang Gung Univ Sci & Technol, Dept Nursing, Taoyuan, Taiwan
关键词
ADHD; comorbidity; testosterone; epidemiology; psychostimulant; ENDOCRINE DISRUPTORS; STIMULANT MEDICATION; TESTOSTERONE; EXPOSURE; PARAMETERS; CHILDREN; SYSTEM; BRAIN;
D O I
10.1089/cap.2018.0126
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: Treating attention-deficit/hyperactivity disorder (ADHD) with methylphenidate (MPH) has become increasingly common, while both animal studies and case reports have previously suggested that MPH may exert adverse effects on the reproductive system or gonadal hormones. This study aims to investigate whether long-term MPH treatment of boys with ADHD can induce testicular dysfunction (TD). Methods: A nationwide cohort that included 59,746 boys diagnosed with ADHD and 52,008 healthy subjects retrieved from the National Health Insurance database in Taiwan was also observed between 1999 and 2011. TD was defined by the International Classification of Diseases, 9th revision, Clinical Modifications codes (257.0, 257.1, 257.2, 257.8, or 257.9). Cumulative time of MPH use was categorized into nonuse, short-term use (1-365 days), and long-term use (>365 days). We compared the rate of TD diagnosis between ADHD patients and controls and analyzed the risk of developing a TD after MPH treatment. Results: Compared with the control group (0.06%), the ADHD group had a higher comorbidity rate of TD (0.14%) (adjusted odds ratio [aOR] = 1.95, 95% confidence interval [95% CI]: 1.26-3.04, p = 0.003). However, MPH did not significantly influence the risk of developing TD (adjusted hazard ratio = 1.40, 95% CI: 0.77-2.54, p = 0.272). Compared with ADHD boys without MPH treatment, patients who were prescribed short-term MPH (aOR = 0.96, 95% CI: 0.51-1.82, p = 0.900) and long-term MPH (aOR = 1.40, 95% CI: 0.69-2.83, p = 0.351) showed no significance associated with an increased risk of developing TD. Conclusions: Our nationwide cohort showed that long-term treatment with MPH has no harmful effect on the testosterone function of ADHD patients. However, due to the increased comorbidity rate of ADHD and TD, early recognition and detection of TD in ADHD children have the potential to change the trajectory of TD morbidity later in life.
引用
收藏
页码:433 / 438
页数:6
相关论文
共 50 条
  • [21] Long-term academic outcomes of attention-deficit hyperactivity disorder and effects of treatment
    Hodgkins, Paul
    Kahle, Jennifer
    Kewley, Geoff
    Madhoo, Manisha
    Arnold, L. Eugene
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2013, 22 : S231 - S232
  • [22] Long-term treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD)
    Hechtman L.
    Current Psychiatry Reports, 2006, 8 (5) : 398 - 408
  • [23] Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?
    Hammerness, Paul G.
    Karampahtsis, Chris
    Babalola, Ronke
    Alexander, Mark E.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (04) : 543 - 551
  • [24] Update on Long-term Stimulant Medication Treatment of Attention-Deficit Hyperactivity Disorder
    Barbaresi, William J.
    JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2014, 35 (07): : 446 - 447
  • [25] OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder
    Antoni Ramos-Quiroga, J.
    Corominas, Margarida
    Castells, Xavier
    Bosch, Rosa
    Casas, Miguel
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (08) : 1121 - 1131
  • [26] Trichotillomania in Attention-Deficit/Hyperactivity Disorder Under Methylphenidate Treatment
    Kara, Tayfun
    Akaltun, Ismail
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2017, 37 (04) : 484 - 484
  • [27] Methylphenidate transdermal system for the treatment of attention-deficit/hyperactivity disorder
    Rugino, Thomas
    FUTURE NEUROLOGY, 2007, 2 (06) : 613 - 620
  • [28] An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/hyperactivity disorder
    Froelich, Jan
    Banaschewski, Tobias
    Doepfner, Manfred
    Goertz-Dorten, Anja
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (08) : 1169 - 1183
  • [29] Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate
    Wolraich, ML
    Doffing, MA
    CNS DRUGS, 2004, 18 (04) : 243 - 250
  • [30] Methylphenidate Treatment and Dyskinesia in Children with Attention-Deficit/Hyperactivity Disorder
    Balazs, Judit
    Dallos, Gyoengyver
    Kereszteny, Agnes
    Czobor, Pal
    Gadoros, Julia
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2011, 21 (02) : 133 - 138